MCID: SLV012
MIFTS: 49

Salivary Gland Adenoid Cystic Carcinoma

Categories: Rare diseases, Cancer diseases, Oral diseases, Gastrointestinal diseases, Endocrine diseases

Aliases & Classifications for Salivary Gland Adenoid Cystic Carcinoma

MalaCards integrated aliases for Salivary Gland Adenoid Cystic Carcinoma:

Name: Salivary Gland Adenoid Cystic Carcinoma 12 52 14
Adenoid Cystic Carcinoma 12 50 69
Cylindroma 12 50
Adenoid Cystic Carcinoma of Salivary Gland 69
Carcinoma, Adenoid Cystic 42
Eccrine Dermal Cylindroma 69
Carcinoma Adenoid Cystic 52
Adenoid Cystic Cancer 12
Adenocystic Carcinoma 50
Carcinoma, Cribriform 69
Cribriform Carcinoma 50
Cylindroma Nos 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4866
MeSH 42 D003528
NCIt 47 C2970
UMLS 69 C0010606

Summaries for Salivary Gland Adenoid Cystic Carcinoma

NIH Rare Diseases : 50 adenoid cystic carcinoma (acc) is a rare form of adenocarcinoma, a type of cancer that begins in glandular tissues. it most commonly arises in the major and minor salivary glands of the head and neck. it can also occur in the breast, uterus, or other locations in the body. symptoms depend on the tumor's location. salivary gland tumors may cause painless masses in the mouth or face. tumors of the lacrimal gland may cause a bulging eye or changes in vision. those affecting the windpipe or voice box may cause respiratory symptoms or changes in speech, respectively. advanced tumors may cause pain and/or nerve paralysis, as acc often spreads along the nerves. it may also spread through the bloodstream. it spreads to the lymph nodes in about 5% to 10% of cases. the cause of acc is currently unknown. it typically does not run in families. treatment depends on many factors and may include surgery, radiation, and/or chemotherapy. unfortunately, acc is typically an aggressive form of cancer that has a poor long-term outlook. last updated: 6/21/2017

MalaCards based summary : Salivary Gland Adenoid Cystic Carcinoma, also known as adenoid cystic carcinoma, is related to laryngeal adenoid cystic carcinoma and cervical adenoid cystic carcinoma, and has symptoms including pain An important gene associated with Salivary Gland Adenoid Cystic Carcinoma is KIT (KIT Proto-Oncogene Receptor Tyrosine Kinase), and among its related pathways/superpathways are Endometrial cancer and Wnt / Hedgehog / Notch. The drugs Fentanyl and Doxepin have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, lung and brain, and related phenotypes are Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) and growth/size/body region

Disease Ontology : 12 A salivary gland carcinoma that is characterized by a distinctive pattern in which abnormal nests or cords of epithelial cells surround and/or infiltrate ducts or glandular structures within the affected organ. These structures are typically filled with a mucous-like material or contain abnormal fibrous membranes.

Wikipedia : 72 Adenoid cystic carcinoma (sometimes referred to as adenocyst, malignant cylindroma, adenocystic,... more...

Related Diseases for Salivary Gland Adenoid Cystic Carcinoma

Diseases related to Salivary Gland Adenoid Cystic Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 71)
id Related Disease Score Top Affiliating Genes
1 laryngeal adenoid cystic carcinoma 26.9 AQP1 BCL2 CCND1 CDH1 CTTN CYLD
2 cervical adenoid cystic carcinoma 12.3
3 maxillary sinus adenoid cystic carcinoma 12.2
4 lacrimal gland adenoid cystic carcinoma 12.2
5 breast adenoid cystic carcinoma 12.2
6 esophageal adenoid cystic carcinoma 12.2
7 bartholin's gland adenoid cystic carcinoma 12.2
8 malignant cylindroma 12.1
9 cribriform carcinoma 12.1
10 prostate adenoid cystic carcinoma 12.1
11 lung adenoid cystic carcinoma 12.1
12 trachea adenoid cystic carcinoma 12.1
13 ethmoid sinus adenoid cystic carcinoma 12.1
14 adnexal spiradenoma/cylindroma of a sweat gland 12.1
15 poncet-spiegler's cylindroma 12.1
16 adenoid cystic carcinoma of the corpus uteri 12.0
17 cutaneous adenocystic carcinoma 12.0
18 brooke-spiegler syndrome 11.8
19 cylindromatosis, familial 11.8
20 lymph node adenoid cystic carcinoma 11.0
21 adenoiditis 10.9
22 lysosomal storage disease 10.6 BCL2 CCND1
23 solitary plasmacytoma of chest wall 10.6 BCL2 CCND1
24 hypersplenism 10.6 AQP1 BCL2
25 small intestinal vasoactive intestinal peptide producing tumor 10.5 KIT NOS2
26 plantar verrucous skin carcinoma 10.5 CDH1 RUNX3
27 pseudounicornuate uterus 10.5 KIT MKI67
28 gastric adenocarcinoma 10.4 MKI67 PCNA
29 punctate palmoplantar keratoderma type 2 10.4 KIT MKI67
30 boylan dew greco syndrome 10.4 MKI67 PCNA
31 spiradenoma 10.3
32 orbital lymphoma 10.3 MKI67 PCNA
33 pylorus cancer 10.3 BCL2 PCNA
34 stenosis of lacrimal punctum 10.3 CCND1 CTTN
35 amyotrophic lateral sclerosis type 10 10.3 CDH1 NOS2
36 chorioangioma 10.3 CCND1 CTTN
37 polyosteolysis/hyperostosis syndrome 10.3 CCND1 KIT MKI67
38 histiocytoma 10.3 CCND1 KIT PCNA
39 hip subluxation 10.3 BCL2 CCND1 MKI67
40 oral antidiabetic drugs toxicity or dose selection 10.2 BCL2 CCND1 MKI67
41 rectal neoplasm 10.2 KIT MKI67
42 gastrointestinal neuroendocrine tumor 10.2 CCND1 CDH1 KIT
43 gallbladder cancer 10.2 CCND1 CDH1 KIT
44 brown-vialetto-van laere syndrome 10.2 CCND1 CDH1 KIT
45 nail disorder, nonsyndromic congenital, 1 10.2 BCL2 CCND1 CDH1
46 orbital lymphangioma 10.1 CCND1 CDH1 PCNA
47 infantile-onset axonal motor and sensory neuropathy-optic atrophy-neurodegenerative syndrome 10.1 CCND1 CDH1 MKI67
48 pediatric meningioma 10.1 MKI67 PCNA
49 enamel hypoplasia cataract hydrocephaly 10.1 KIT MKI67
50 sparse hair ptosis mental retardation 10.1 BCL2 MKI67

Graphical network of the top 20 diseases related to Salivary Gland Adenoid Cystic Carcinoma:



Diseases related to Salivary Gland Adenoid Cystic Carcinoma

Symptoms & Phenotypes for Salivary Gland Adenoid Cystic Carcinoma

UMLS symptoms related to Salivary Gland Adenoid Cystic Carcinoma:


pain

GenomeRNAi Phenotypes related to Salivary Gland Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 8.8 CCND1 MKI67 PCNA

MGI Mouse Phenotypes related to Salivary Gland Adenoid Cystic Carcinoma:

44 (show all 14)
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.2 EN1 KIT NOS2 PCNA RUNX3 AQP1
2 endocrine/exocrine gland MP:0005379 10.18 AQP1 BCL2 CCND1 CDH1 CYLD EN1
3 cellular MP:0005384 10.16 BCL2 CCND1 CDH1 CTTN CYLD EN1
4 behavior/neurological MP:0005386 10.14 AQP1 BCL2 CCND1 CYLD EN1 KIT
5 cardiovascular system MP:0005385 10.13 BCL2 CCND1 CDH1 CTTN EN1 KIT
6 hematopoietic system MP:0005397 10.13 AQP1 BCL2 CCND1 CTTN CYLD EN1
7 immune system MP:0005387 10.07 KIT NOS2 PCNA RUNX3 BCL2 CCND1
8 homeostasis/metabolism MP:0005376 10.06 AQP1 BCL2 CCND1 CDH1 CYLD EN1
9 digestive/alimentary MP:0005381 10.04 BCL2 CCND1 CDH1 CYLD KIT NOS2
10 mortality/aging MP:0010768 10.03 KIT NOS2 PCNA RUNX3 WIF1 AQP1
11 integument MP:0010771 9.92 BCL2 CCND1 CDH1 CYLD EN1 KIT
12 neoplasm MP:0002006 9.7 BCL2 CCND1 CDH1 CYLD KIT NOS2
13 reproductive system MP:0005389 9.61 AQP1 BCL2 CCND1 CDH1 CTTN EN1
14 respiratory system MP:0005388 9.23 AQP1 BCL2 CCND1 CTTN CYLD KIT

Drugs & Therapeutics for Salivary Gland Adenoid Cystic Carcinoma

Drugs for Salivary Gland Adenoid Cystic Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 98)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2
Doxepin Approved Phase 3 1668-19-5 667477 667468
3
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
4
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
5 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
6 Liver Extracts Phase 3,Phase 1
7 Adjuvants, Anesthesia Phase 3
8 Analgesics Phase 3
9 Analgesics, Opioid Phase 3
10 Anesthetics Phase 3
11 Anesthetics, General Phase 3
12 Anesthetics, Intravenous Phase 3
13 Central Nervous System Depressants Phase 3
14 Narcotics Phase 3
15 Peripheral Nervous System Agents Phase 3
16 Antidepressive Agents Phase 3
17 Antidepressive Agents, Tricyclic Phase 3
18 Histamine Antagonists Phase 3
19
Histamine Phosphate Phase 3 51-74-1 65513
20 Neurotransmitter Agents Phase 3
21 Psychotropic Drugs Phase 3
22 Autonomic Agents Phase 3
23 Cholinergic Agents Phase 3
24 Cola Nutraceutical Phase 3,Phase 1
25
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
26
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
27
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
28
Gemcitabine Approved Phase 2 95058-81-4 60750
29
Trastuzumab Approved, Investigational Phase 2,Phase 1 180288-69-1 9903
30
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904
31
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
32
Bevacizumab Approved, Investigational Phase 1, Phase 2 216974-75-3
33
Cetuximab Approved Phase 1, Phase 2 205923-56-4 56842117 2333
34
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
35
nivolumab Approved Phase 2 946414-94-4
36
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
37
Lenvatinib Approved Phase 2 417716-92-8
38
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
39
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
40
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
41
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 43805 6857599
42
Lapatinib Approved March 2007, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
43
Doxil Approved June 1999 Phase 2 31703
44 Immunosuppressive Agents Phase 2,Phase 1
45 Angiogenesis Inhibitors Phase 2,Phase 1
46 Angiogenesis Modulating Agents Phase 2,Phase 1
47 Protein Kinase Inhibitors Phase 2,Phase 1
48 Imatinib Mesylate Phase 2 123596
49 Anti-Bacterial Agents Phase 2,Phase 1
50 Antibiotics, Antitubercular Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 53)

id Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
3 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
4 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
5 A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands Completed NCT00886132 Phase 2 Sunitinib
6 A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands Completed NCT01678105 Phase 2 Dovitinib
7 Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers Completed NCT00095563 Phase 2 lapatinib ditosylate
8 Imatinib Mesylate in Treating Patients With Salivary Gland Cancer Completed NCT00045669 Phase 2 imatinib mesylate
9 Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck Completed NCT00077428 Phase 2 bortezomib;doxorubicin hydrochloride
10 Gemcitabine in Treating Patients With Recurrent or Metastatic Adenoid Cystic Cancer of the Head and Neck Completed NCT00017498 Phase 2 gemcitabine hydrochloride
11 Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer Completed NCT00004163 Phase 2 Trastuzumab
12 Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery Completed NCT00003744 Phase 2 gemcitabine
13 Cisplatin or Carboplatin Combined With Gemcitabine in Treating Patients With Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor Completed NCT00079079 Phase 2 carboplatin;cisplatin;gemcitabine hydrochloride
14 Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
15 Iressa Study in Patients With Salivary Gland Cancer Completed NCT00509002 Phase 2 Gefitinib
16 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
17 Nivolumab and Ipilimumab in Treating Patients With Metastatic Recurrent Major or Minor Salivary Gland Cancer Recruiting NCT03146650 Phase 2
18 Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer Recruiting NCT03172624 Phase 2 Nivolumab;Ipilimumab
19 Axitinib in R/M Salivary Gland Cancers of the Upper Aerodigestive Tract - SGC-AX14 Recruiting NCT02857712 Phase 2 Axitinib
20 18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Recruiting NCT01806675 Phase 1, Phase 2 fludeoxyglucose F 18;2-fluoropropionyl-labeled pegylated dimeric RGD peptide
21 Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands: ACC-LEN14 Active, not recruiting NCT02860936 Phase 2 Lenvatinib
22 Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors Active, not recruiting NCT00859937 Phase 2 dasatinib
23 Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma Active, not recruiting NCT01175980 Phase 2 Vorinostat
24 Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma Active, not recruiting NCT01604772 Phase 2 Akt Inhibitor MK2206
25 Phase II Study of Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma Active, not recruiting NCT02393820 Phase 2 pazopanib
26 Title XELOX FOR SALIVARY GLAND CANCERS Terminated NCT00101075 Phase 2 Capecitabine;Oxaliplatin
27 MRI Mapping in Planning Radiation Therapy to the Base of Skull and Brain in Patients With Nonmetastatic Head and Neck Cancer Unknown status NCT00984074 Phase 1
28 Head & Neck Cancer Survivorship: Physical and Functional Status Completed NCT00751816 Phase 1 systemic chemotherapy
29 Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors Completed NCT00089362 Phase 1 alvespimycin hydrochloride
30 Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00023959 Phase 1 hydroxyurea;fluorouracil
31 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
32 Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer Completed NCT01637194 Phase 1 everolimus
33 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
34 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
35 Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Completed NCT00397384 Phase 1 cetuximab;erlotinib hydrochloride
36 Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer Completed NCT00004065 Phase 1 tanespimycin
37 Stereotactic Radiosurgery in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer Active, not recruiting NCT00851253 Phase 1
38 Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer Active, not recruiting NCT00470496 Phase 1 HPPH;photodynamic therapy
39 Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer Unknown status NCT00499733 cyclophosphamide
40 Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer Completed NCT00897793
41 Family Quality of Life Among Families With a Member Who is a Cancer Patient Completed NCT00544336
42 PET Scans in Patients With Head And Neck Cancer Who Are Undergoing 3-Dimensional Conformal Radiation Therapy And Intensity-Modulated Radiation Therapy Completed NCT00809016
43 Using Traditional Acupuncture in the Management of Cancer Treatment Related Lymphoedema Completed NCT00828516
44 Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer Completed NCT00068497 gefitinib
45 L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer Completed NCT01155609
46 Immunoreactivity to Cetuximab in Cancer Patients Completed NCT00896896
47 Customized Headrest or Standard Headrest in Holding Patients Still While Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00973947
48 Collecting and Storing Tissue Samples From Patients With Head and Neck Cancer Completed NCT00898300
49 Side Effects of High-Dose Intensity-Modulated Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00415025
50 Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants Recruiting NCT00898638

Search NIH Clinical Center for Salivary Gland Adenoid Cystic Carcinoma

Cochrane evidence based reviews: carcinoma, adenoid cystic

Genetic Tests for Salivary Gland Adenoid Cystic Carcinoma

Anatomical Context for Salivary Gland Adenoid Cystic Carcinoma

MalaCards organs/tissues related to Salivary Gland Adenoid Cystic Carcinoma:

39
Salivary Gland, Lung, Brain, Lymph Node, Eye, Trachea, Uterus

Publications for Salivary Gland Adenoid Cystic Carcinoma

Articles related to Salivary Gland Adenoid Cystic Carcinoma:

(show top 50) (show all 66)
id Title Authors Year
1
Risk of Nodal Metastasis in Major Salivary Gland Adenoid Cystic Carcinoma. ( 28168897 )
2017
2
Association between high expression of phosphorylated Akt and mammalian target of rapamycin and improved survival in salivary gland adenoid cystic carcinoma. ( 28230926 )
2017
3
Biochemical changes of salivary gland adenoid cystic carcinoma cells induced by SGI-1776. ( 28228352 )
2017
4
Correction: Whole-Genome Sequencing of Salivary Gland Adenoid Cystic Carcinoma. ( 28642227 )
2017
5
MYB, MYBL1, MYBL2 and NFIB gene alterations and MYC overexpression in salivary gland adenoid cystic carcinoma. ( 28594149 )
2017
6
B7-H3 regulates migration and invasion in salivary gland adenoid cystic carcinoma via the JAK2/STAT3 signaling pathway. ( 28386362 )
2017
7
Risk factors and prognosis for salivary gland adenoid cystic carcinoma in southern china: A 25-year retrospective study. ( 28151884 )
2017
8
Early stage minor salivary gland adenoid cystic carcinoma has favourable prognosis. ( 28600602 )
2017
9
Type III TGF-I^ receptor inhibits cell proliferation and migration in salivary glands adenoid cystic carcinoma by suppressing NF-I_B signaling. ( 26531330 )
2016
10
Carcinoma-Associated Fibroblasts Lead the Invasion of Salivary Gland Adenoid Cystic Carcinoma Cells by Creating an Invasive Track. ( 26954362 )
2016
11
Downregulation of nucleophosmin expression inhibited proliferation and induced apoptosis in salivary gland adenoid cystic carcinoma. ( 27501253 )
2016
12
Whole-Genome Sequencing of Salivary Gland Adenoid Cystic Carcinoma. ( 26862087 )
2016
13
Identification of methylated genes in salivary gland adenoid cystic carcinoma xenografts using global demethylation and methylation microarray screening. ( 27212063 )
2016
14
PAK2 promotes migration and proliferation of salivary gland adenoid cystic carcinoma. ( 27648129 )
2016
15
Recurrent Fusions in MYB and MYBL1 Define a Common, Transcription Factor-Driven Oncogenic Pathway in Salivary Gland Adenoid Cystic Carcinoma. ( 26631070 )
2016
16
Inhibitory effects of silibinin on proliferation and lung metastasis of human high metastasis cell line of salivary gland adenoid cystic carcinoma via autophagy induction. ( 27822066 )
2016
17
Adding concurrent chemotherapy to postoperative radiotherapy improves locoregional control but Not overall survival in patients with salivary gland adenoid cystic carcinoma-a propensity score matched study. ( 27000157 )
2016
18
MicroRNA-101-3p suppresses cell proliferation, invasion and enhances chemotherapeutic sensitivity in salivary gland adenoid cystic carcinoma by targeting Pim-1. ( 26693056 )
2015
19
Inhibition of STAT3 reduces proliferation and invasion in salivary gland adenoid cystic carcinoma. ( 26175943 )
2015
20
Role of hypoxia-inducible factor-1I+ and CD146 in epidermal growth factor receptor-mediated angiogenesis in salivary gland adenoid cystic carcinoma. ( 25997612 )
2015
21
Salivary gland adenoid cystic carcinoma. ( 26214665 )
2015
22
Aberrant Wnt-1/beta-catenin signaling and WIF-1 deficiency are important events which promote tumor cell invasion and metastasis in salivary gland adenoid cystic carcinoma. ( 26405993 )
2015
23
Differential expression of vascular endothelial growth factor in high- and low-metastasis cell lines of salivary gland adenoid cystic carcinoma. ( 24510998 )
2014
24
Inhibition of mTOR reduce Stat3 and PAI related angiogenesis in salivary gland adenoid cystic carcinoma. ( 25520866 )
2014
25
High expression of SOX2 is associated with poor prognosis in patients with salivary gland adenoid cystic carcinoma. ( 24828201 )
2014
26
Aquaporin-1 promoter hypermethylation is associated with improved prognosis in salivary gland adenoid cystic carcinoma. ( 24493792 )
2014
27
A study on the inhibition of VEGF expression in salivary gland adenoid cystic carcinoma cells via iNOS gene RNAi in vitro. ( 25065562 )
2014
28
Pim-1 acts as an oncogene in human salivary gland adenoid cystic carcinoma. ( 25551195 )
2014
29
19-year oncologic outcomes and the benefit of elective neck dissection in salivary gland adenoid cystic carcinoma. ( 24170702 )
2013
30
Expression of podoplanin in salivary gland adenoid cystic carcinoma and its association with distant metastasis and clinical outcomes. ( 22580922 )
2012
31
High expression of the autophagy gene Beclin-1 is associated with favorable prognosis for salivary gland adenoid cystic carcinoma. ( 22712799 )
2012
32
Developmental transcription factor EN1--a novel biomarker in human salivary gland adenoid cystic carcinoma. ( 21800291 )
2012
33
Salivary gland adenoid cystic carcinoma with cervical lymph node metastasis: a preliminary study of 62 cases. ( 22647764 )
2012
34
Unfavorable clinical implications for hypermethylation of RUNX3 in patients with salivary gland adenoid cystic carcinoma. ( 21567090 )
2011
35
Integrated, genome-wide screening for hypomethylated oncogenes in salivary gland adenoid cystic carcinoma. ( 21551254 )
2011
36
Metastatic pleural effusion: a rare presentation of salivary gland adenoid cystic carcinoma. ( 21545072 )
2011
37
Maslinic acid induces apoptosis in salivary gland adenoid cystic carcinoma cells by Ca2+-evoked p38 signaling pathway. ( 21279332 )
2011
38
Critical regions and spreading of runt-related transcription factor-3 C-phosphate-G (CpG) island methylation in human salivary gland adenoid cystic carcinoma. ( 21658745 )
2011
39
Expression of the membrane-cytoskeletal linker Ezrin in salivary gland adenoid cystic carcinoma. ( 21550270 )
2011
40
CpG island methylation profiling in human salivary gland adenoid cystic carcinoma. ( 21692051 )
2011
41
[Evolution pattern of the Runx3 gene 5'-CpG island methylation in human salivary gland adenoid cystic carcinoma]. ( 21223798 )
2010
42
[RUNX3 expression and its methylation of 5'-CpG island in salivary gland adenoid cystic carcinoma cell lines ACC-2, ACC-3 and ACC-M]. ( 21223819 )
2010
43
RNAi knockdown of C-erbB2 expression inhibits salivary gland adenoid cystic carcinoma SACC-83 cell growth in vitro. ( 23554633 )
2010
44
Response to oxaliplatin with cetuximab in minor salivary gland adenoid cystic carcinoma. ( 19688981 )
2009
45
[Effects of Ezrin gene on the proliferation and invasion activity of human salivary gland adenoid cystic carcinoma]. ( 19575999 )
2009
46
Sulforaphane induces G2-M arrest and apoptosis in high metastasis cell line of salivary gland adenoid cystic carcinoma. ( 19589718 )
2009
47
Synergistic inhibitory effect of sulforaphane and 5-fluorouracil in high and low metastasis cell lines of salivary gland adenoid cystic carcinoma. ( 18844240 )
2009
48
NF-kappaB promotes iNOS and VEGF expression in salivary gland adenoid cystic carcinoma cells and enhances endothelial cell motility in vitro. ( 19317804 )
2009
49
Survival from salivary glands adenoid cystic carcinoma in European populations. ( 19095489 )
2009
50
High expression of Polycomb group protein EZH2 predicts poor survival in salivary gland adenoid cystic carcinoma. ( 18326020 )
2008

Variations for Salivary Gland Adenoid Cystic Carcinoma

ClinVar genetic disease variations for Salivary Gland Adenoid Cystic Carcinoma:

6 (show all 14)
id Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
2 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
3 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
4 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
5 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
6 PIK3CA NM_006218.3(PIK3CA): c.1258T> C (p.Cys420Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913272 GRCh37 Chromosome 3, 178927980: 178927980
7 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
8 IDH1 NM_001282386.1(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh38 Chromosome 2, 208248388: 208248388
9 PIK3CA NM_006218.3(PIK3CA): c.3129G> A (p.Met1043Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913283 GRCh37 Chromosome 3, 178952074: 178952074
10 TP53 NM_000546.5(TP53): c.638G> C (p.Arg213Pro) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
11 IDH1 NM_005896.3(IDH1): c.395G> T (p.Arg132Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh37 Chromosome 2, 209113112: 209113112
12 IDH1 NM_001282387.1(IDH1): c.394C> T (p.Arg132Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh37 Chromosome 2, 209113113: 209113113
13 IDH1 NM_001282387.1(IDH1): c.394C> G (p.Arg132Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh37 Chromosome 2, 209113113: 209113113
14 IDH1 NM_001282387.1(IDH1): c.394C> A (p.Arg132Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh37 Chromosome 2, 209113113: 209113113

Cosmic variations for Salivary Gland Adenoid Cystic Carcinoma:

9 (show top 50) (show all 2127)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM1659071 WASF2 salivary gland,mouth,carcinoma,adenoid cystic carcinoma c.15G>T p.T5T 25
2 COSM1659031 TRPV5 salivary gland,mouth,carcinoma,adenoid cystic carcinoma c.554A>G p.H185R 25
3 COSM1658989 TP53BP1 salivary gland,mouth,carcinoma,adenoid cystic carcinoma c.3854C>G p.T1285S 25
4 COSM43878 TP53 salivary gland,major,carcinoma,adenoid cystic carcinoma c.427G>A p.V143M 25
5 COSM1659046 THRA salivary gland,mouth,carcinoma,adenoid cystic carcinoma c.1162C>T p.R388W 25
6 COSM1658912 SLC26A2 salivary gland,mouth,carcinoma,adenoid cystic carcinoma c.1474C>T p.R492W 25
7 COSM1659033 RNF38 salivary gland,mouth,carcinoma,adenoid cystic carcinoma c.623A>G p.H208R 25
8 COSM1659036 MELK salivary gland,mouth,carcinoma,adenoid cystic carcinoma c.817T>C p.W273R 25
9 COSM1659003 MAP2 salivary gland,mouth,carcinoma,adenoid cystic carcinoma c.31G>T p.A11S 25
10 COSM51382 KRAS salivary gland,mouth,carcinoma,adenoid cystic carcinoma c.50G>A p.S17N 25
11 COSM51381 KIT salivary gland,face,carcinoma,adenoid cystic carcinoma c.2386A>G p.R796G 25
12 COSM1658780 KDM6A salivary gland,mouth,carcinoma,adenoid cystic carcinoma c.2833-1G>A p.? 25
13 COSM1658957 HNRNPDL salivary gland,mouth,carcinoma,adenoid cystic carcinoma c.289C>T p.R97C 25
14 COSM1658892 HK1 salivary gland,mouth,carcinoma,adenoid cystic carcinoma c.370C>G p.H124D 25
15 COSM1659047 HECTD4 salivary gland,mouth,carcinoma,adenoid cystic carcinoma c.6707G>A p.S2236N 25
16 COSM1658983 GTF3C3 salivary gland,mouth,carcinoma,adenoid cystic carcinoma c.2602C>G p.Q868E 25
17 COSM1658965 DYRK4 salivary gland,mouth,carcinoma,adenoid cystic carcinoma c.1733G>A p.R578H 25
18 COSM1658899 COL22A1 salivary gland,mouth,carcinoma,adenoid cystic carcinoma c.4115G>C p.G1372A 25
19 COSM1658935 CHEK2 salivary gland,mouth,carcinoma,adenoid cystic carcinoma c.508G>A p.V170I 25
20 COSM1658880 CDAN1 salivary gland,mouth,carcinoma,adenoid cystic carcinoma c.2248G>T p.G750C 25
21 COSM51383 BRAF salivary gland,mouth,carcinoma,adenoid cystic carcinoma c.1768G>A p.V590I 25
22 COSM34223 AXL salivary gland,mouth,carcinoma,adenoid cystic carcinoma c.1522G>A p.G508S 25
23 COSM1658913 salivary gland,mouth,carcinoma,adenoid cystic carcinoma c.1657G>A p.G553R 25
24 COSM1658893 salivary gland,mouth,carcinoma,adenoid cystic carcinoma c.358C>G p.H120D 25
25 COSM1658951 salivary gland,mouth,carcinoma,adenoid cystic carcinoma c.236G>A p.R79H 25
26 COSM1658894 salivary gland,mouth,carcinoma,adenoid cystic carcinoma c.355C>G p.H119D 25
27 COSM1659048 salivary gland,mouth,carcinoma,adenoid cystic carcinoma c.7457G>A p.S2486N 25
28 COSM1659004 salivary gland,mouth,carcinoma,adenoid cystic carcinoma c.31G>T p.A11S 25
29 COSM1658882 ZNF507 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.34C>A p.P12T 24
30 COSM1658927 VWA8 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.4027G>A p.E1343K 24
31 COSM1658946 VWA5B1 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.1486G>A p.V496I 24
32 COSM1658865 UNC80 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.305A>G p.Q102R 24
33 COSM1659017 UBTF salivary gland,NS,carcinoma,adenoid cystic carcinoma c.106A>T p.N36Y 24
34 COSM1659040 UBTF salivary gland,NS,carcinoma,adenoid cystic carcinoma c.100A>C p.M34L 24
35 COSM1659032 TXNRD3 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.412A>G p.K138E 24
36 COSM1659053 TSC1 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.3280G>T p.E1094* 24
37 COSM43614 TP53 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.854A>C p.E285A 24
38 COSM1659070 TOMM34 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.555T>A p.P185P 24
39 COSM1658929 TOM1L2 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.259G>A p.V87I 24
40 COSM34221 TIE1 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.2050G>C p.A684P 24
41 COSM1658909 TFAP2D salivary gland,NS,carcinoma,adenoid cystic carcinoma c.1306C>T p.R436W 24
42 COSM1659024 TBC1D31 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.845T>A p.L282Q 24
43 COSM1658982 TANGO6 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.352G>C p.G118R 24
44 COSM1658994 SUPT5H salivary gland,NS,carcinoma,adenoid cystic carcinoma c.1094G>T p.R365L 24
45 COSM1658977 STXBP3 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.1275G>C p.R425S 24
46 COSM3863360 SPEN salivary gland,NS,carcinoma,adenoid cystic carcinoma c.4207C>T p.R1403* 24
47 COSM1659068 SOX6 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.630T>C p.D210D 24
48 COSM1658954 SMARCA2 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.2564G>A p.R855Q 24
49 COSM1659007 SMARCA2 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.3476G>T p.R1159L 24
50 COSM1659023 SMARCA2 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.4582T>A p.S1528T 24

Copy number variations for Salivary Gland Adenoid Cystic Carcinoma from CNVD:

7 (show top 50) (show all 209)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13805 1 1 61300000 Deletion Adenoid cystic carcinoma
2 31809 1 31200000 32688000 Loss BAI2 Adenoid cystic carcinoma
3 31810 1 31200000 32688000 Loss EIF3S2 Adenoid cystic carcinoma
4 31811 1 31200000 32688000 Loss FABP3 Adenoid cystic carcinoma
5 31812 1 31200000 32688000 Loss HDAC1 Adenoid cystic carcinoma
6 31813 1 31200000 32688000 Loss IQCC Adenoid cystic carcinoma
7 31814 1 31200000 32688000 Loss KHDRBS1 Adenoid cystic carcinoma
8 31815 1 31200000 32688000 Loss LCK Adenoid cystic carcinoma
9 31816 1 31200000 32688000 Loss MARCKSL1 Adenoid cystic carcinoma
10 31817 1 31200000 32688000 Loss PTP4A2 Adenoid cystic carcinoma
11 31818 1 31200000 32688000 Loss PUM1 Adenoid cystic carcinoma
12 31819 1 31200000 32688000 Loss RBBP4 Adenoid cystic carcinoma
13 31820 1 31200000 32688000 Loss SERINC2 Adenoid cystic carcinoma
14 31821 1 31200000 32688000 Loss TXLNA Adenoid cystic carcinoma
15 33928 1 50618000 52179000 Loss CDKN2C Adenoid cystic carcinoma
16 33929 1 50618000 52179000 Loss EPS15 Adenoid cystic carcinoma
17 33930 1 50618000 52179000 Loss FAF1 Adenoid cystic carcinoma
18 33931 1 50618000 52179000 Loss NRD1 Adenoid cystic carcinoma
19 33932 1 50618000 52179000 Loss RAB3B Adenoid cystic carcinoma
20 33933 1 50618000 52179000 Loss RNF11 Adenoid cystic carcinoma
21 50143 11 114500000 121200000 Deletion Adenoid cystic carcinoma
22 50146 11 114500000 121200000 Gain Salivary gland adenoid cystic carcinoma
23 58545 11 68400000 70400000 Deletion Adenoid cystic carcinoma
24 58546 11 68400000 70400000 Gain Salivary gland adenoid cystic carcinoma
25 61970 12 103800000 109000000 LOH Adenoid cystic carcinoma
26 64283 12 125900000 133851895 LOH Adenoid cystic carcinoma
27 67068 12 35800000 133851895 Loss Adenoid cystic carcinoma
28 67236 12 38200000 58100000 Deletion Adenoid cystic carcinoma
29 67639 12 43743000 50676000 Loss ACVR1B Adenoid cystic carcinoma
30 67640 12 43743000 50676000 Loss ACVRL1 Adenoid cystic carcinoma
31 67641 12 43743000 50676000 Loss ADCY6 Adenoid cystic carcinoma
32 67642 12 43743000 50676000 Loss AMIGO2 Adenoid cystic carcinoma
33 67643 12 43743000 50676000 Loss ANP32D Adenoid cystic carcinoma
34 67644 12 43743000 50676000 Loss ARF3 Adenoid cystic carcinoma
35 67645 12 43743000 50676000 Loss ATF1 Adenoid cystic carcinoma
36 67646 12 43743000 50676000 Loss CCNT1 Adenoid cystic carcinoma
37 67647 12 43743000 50676000 Loss COL2A1 Adenoid cystic carcinoma
38 67648 12 43743000 50676000 Loss DDX23 Adenoid cystic carcinoma
39 67649 12 43743000 50676000 Loss FAIM2 Adenoid cystic carcinoma
40 67650 12 43743000 50676000 Loss HDAC7A Adenoid cystic carcinoma
41 67651 12 43743000 50676000 Loss LALBA Adenoid cystic carcinoma
42 67652 12 43743000 50676000 Loss LETMD1 Adenoid cystic carcinoma
43 67653 12 43743000 50676000 Loss LIMA1 Adenoid cystic carcinoma
44 67654 12 43743000 50676000 Loss MLL2 Adenoid cystic carcinoma
45 67655 12 43743000 50676000 Loss PFKM Adenoid cystic carcinoma
46 67656 12 43743000 50676000 Loss PLEKHA9 Adenoid cystic carcinoma
47 67657 12 43743000 50676000 Loss PRKAG1 Adenoid cystic carcinoma
48 67658 12 43743000 50676000 Loss RACGAP1 Adenoid cystic carcinoma
49 67659 12 43743000 50676000 Loss RAPGEF3 Adenoid cystic carcinoma
50 67660 12 43743000 50676000 Loss RHEBL1 Adenoid cystic carcinoma

Expression for Salivary Gland Adenoid Cystic Carcinoma

Search GEO for disease gene expression data for Salivary Gland Adenoid Cystic Carcinoma.

Pathways for Salivary Gland Adenoid Cystic Carcinoma

GO Terms for Salivary Gland Adenoid Cystic Carcinoma

Cellular components related to Salivary Gland Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cortical cytoskeleton GO:0030863 8.62 CTTN NOS2

Biological processes related to Salivary Gland Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.62 AQP1 BCL2 CCND1 CDH1
2 focal adhesion assembly GO:0048041 9.46 BCL2 CTTN
3 response to iron ion GO:0010039 9.43 BCL2 CCND1
4 hemopoiesis GO:0030097 9.43 BCL2 KIT RUNX3
5 melanocyte differentiation GO:0030318 9.4 BCL2 KIT
6 developmental pigmentation GO:0048066 9.37 BCL2 KIT
7 response to cadmium ion GO:0046686 9.18 PCNA
8 regulation of developmental pigmentation GO:0048070 9.16 BCL2 KIT
9 lymphoid progenitor cell differentiation GO:0002320 8.96 BCL2 KIT
10 pigmentation GO:0043473 8.8 BCL2 EN1 KIT

Molecular functions related to Salivary Gland Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.73 AQP1 BCL2 CCND1 CDH1 CTTN CYLD
2 proline-rich region binding GO:0070064 8.62 CCND1 CYLD

Sources for Salivary Gland Adenoid Cystic Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....